Zacks Small Cap Research – SNGX: Cycle 3 Data for SGX301 Phase 3 Trial in CTCL Shows Continued Positive Effects…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Cycle 3 Data Shows Continued Efficacy for SGX301 in Phase 3 CTCL Trial On October 22, 2020,…

Continue Reading Zacks Small Cap Research – SNGX: Cycle 3 Data for SGX301 Phase 3 Trial in CTCL Shows Continued Positive Effects…

LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment | Small Molecules

LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment Details Category: Small…

Continue Reading LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment | Small Molecules

Photodynamic Therapy Market to See Huge Growth at a CAGR of 16.6% by 2030 | Impacts Analysis of COVID-19

Market Industry Reports (MIR) has published a new report titled “Photodynamic Therapy Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the Global Photodynamic Therapy…

Continue Reading Photodynamic Therapy Market to See Huge Growth at a CAGR of 16.6% by 2030 | Impacts Analysis of COVID-19

SGX301 Demonstrates Positive Benefits for Cutaneous T-Cell Lymphoma

The Fluorescent Light Activated Synthetic Hypericin (FLASH) study examining SGX301 (synthetic hypericin) to treat patients with cutaneous t-cell lymphoma (CTCL) improved responses for patients and maintained a tolerable safety profile,…

Continue Reading SGX301 Demonstrates Positive Benefits for Cutaneous T-Cell Lymphoma